Literature DB >> 19183921

[52 year-old patient with severe heart failure due to multiple myeloma].

C Morbach1, M Breunig, F Weidemann, M Topp, C Ritter, P Schneider, H Einsele, S Störk, C E Angermann.   

Abstract

Cardiac amyloidosis represents a prognostically relevant comorbidity in multiple myeloma. We report the case of a patient in whom severe heart failure symptoms as a consequence of cardiac AL-amyloidosis resolved after tandem high-dose melphalan therapy followed by autologous blood-stem cell transplantation. Partial regression of cardiac amyloid deposits and improvement of cardiac function were objectified.

Entities:  

Mesh：

Year:  2009        PMID： 19183921     DOI： 10.1007/s00108-008-2241-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  12 in total

1.  Changes in left and right ventricular cardiac function after valve replacement for aortic stenosis determined by cine MR imaging.

Authors:  J J Sandstede; M Beer; S Hofmann; C Lipke; K Harre; T Pabst; W Kenn; S Neubauer; D Hahn
Journal:  J Magn Reson Imaging       Date:  2000-08       Impact factor: 4.813

Review 2.  Therapy for immunoglobulin light chain amyloidosis: the new and the old.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri
Journal:  Blood Rev       Date:  2004-03       Impact factor: 8.250

3.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Raymond Y Kwong; Rodney H Falk
Journal:  Circulation       Date:  2005-01-18       Impact factor: 29.690

4.  Therapy effects of green tea in a patient with systemic light-chain amyloidosis.

Authors:  Derliz Mereles; Erich E Wanker; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2008-03-03       Impact factor: 5.460

Review 5.  State of the art therapy in multiple myeloma and future perspectives.

Authors:  Ulrich Denz; Peter S Haas; Ralph Wäsch; Hermann Einsele; Monika Engelhardt
Journal:  Eur J Cancer       Date:  2006-07-03       Impact factor: 9.162

6.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Alicia Maria Maceira; Jayshree Joshi; Sanjay Kumar Prasad; James Charles Moon; Enrica Perugini; Idris Harding; Mary Noelle Sheppard; Philip Alexander Poole-Wilson; Philip Nigel Hawkins; Dudley John Pennell
Journal:  Circulation       Date:  2005-01-03       Impact factor: 29.690

7.  Non-invasive predictors of survival in cardiac amyloidosis.

Authors:  Arnt V Kristen; Jolanta B Perz; Stefan O Schonland; Ute Hegenbart; Philipp A Schnabel; Joern H Kristen; Hartmut Goldschmidt; Hugo A Katus; Thomas J Dengler
Journal:  Eur J Heart Fail       Date:  2007-03-09       Impact factor: 15.534

8.  99mTc-aprotinin scintigraphy in amyloidosis.

Authors:  Bente K Schaadt; Helle W Hendel; Peter Gimsing; Viggo Jønsson; Heidi Pedersen; Birger Hesse
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

9.  Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis.

Authors:  Jun Koyama; Patricia A Ray-Sequin; Rodney H Falk
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

10.  Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis.

Authors:  J B Perz; A Rahemtulla; C Giles; R M Szydlo; J Davis; D Gopaul; J Gillmore; C J Mathias; P N Hawkins; J F Apperley
Journal:  Bone Marrow Transplant       Date:  2006-05       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.